INDEMNIFICATION AND ADVANCEMENT AGREEMENTIndemnification and Advancement Agreement • January 28th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification and Advancement Agreement (“Agreement”) is made as of ________ __, 20__ by and between Sana Biotechnology, Inc., a Delaware corporation (the “Company”), and ______________, [a member of the Board of Directors/an officer/an employee] of the Company (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering indemnification and advancement.
SANA BIOTECHNOLOGY, INC. STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENTStock Option Agreement • January 13th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
Sana Biotechnology, Inc. (the “Company”), pursuant to its 2018 Equity Incentive Plan (the “Plan”), hereby grants to the participant set forth below (“Participant”), an option (the “Option”) to purchase the number of shares of the Company’s Common Stock (referred to herein as “Shares”) set forth below. This Option is subject to all of the terms and conditions as set forth herein and in the Stock Option Agreement attached hereto as Exhibit A (the “Stock Option Agreement”) and the Plan, each of which is incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Stock Option Grant Notice and the Stock Option Agreement.
AGREEMENT AND PLAN OF MERGER by and among SANA BIOTECHNOLOGY, INC., SANA BIOTECHNOLOGY IV, INC., COBALT BIOMEDICINE, INC. and VENTURELABS VI, INC., solely in its capacity as the Stockholders’ Representative Dated as of December 20, 2018Agreement and Plan of Merger • December 18th, 2020 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
This AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of December 20, 2018, is by and among Sana Biotechnology, Inc., a Delaware corporation (“Parent”), Sana Biotechnology IV, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), Cobalt Biomedicine, Inc., a Delaware corporation (the “Company”), and VentureLabs VI, Inc., a Delaware corporation, solely in its capacity as the Stockholders’ Representative (“Stockholders’ Representative”).
EXCLUSIVE LICENSE AGREEMENT PREAMBLEExclusive License Agreement • December 18th, 2020 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
This agreement (“Agreement”) is made and entered into, effective as of the date of last signature below, (“Effective Date”) by and between: Washington University, a corporation established by special act of the Missouri General Assembly approved February 22, 1853 and acts amendatory thereto, having its principal offices at One Brookings Drive, St. Louis, Missouri 63130 (hereinafter referred to as “WU”); and Sana Biotechnology, Inc. a corporation organized and existing under the laws of the State of Delaware, having its principal offices at 188 E Blaine Street, Suite 400, Seattle, WA 98102 (hereinafter referred to as “Licensee”) and the following correspondence addresses, each a “Party” or collectively the “Parties” of this Agreement:
AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • January 13th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 to Exclusive License Agreement (“Amendment No. 1”), effective as of December 3, 2020 (“Amendment No. 1 Effective Date”), is entered into by and between The Regents of the University of California, a California public corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 (“The Regents”) and acting through its Office of Technology Management, University of California San Francisco (“UCSF”), 600 16th Street, Suite S-272, San Francisco, CA 94143, and Sana Biotechnology, Inc., a Delaware corporation, having a place of business at 188 East Blaine Street, Suite 400, Seattle, WA 98102 (“Licensee”).
EXCLUSIVE LICENSE AGREEMENT BETWEEN THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AND SANA BIOTECHNOLOGY, INC. FORExclusive License Agreement • January 13th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances) • California
THIS EXCLUSIVE LICENSE AGREEMENT AND THE ATTACHED APPENDICES A, B, and C (collectively, the “Agreement”) is made and is effective March 22, 2019 (the “Effective Date”) between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (“The Regents”), a California corporation having its corporate offices located at [***], acting through The Technology Development Group of the University of California, Los Angeles, located at [***], and SANA BIOTECHNOLOGY, INC. (“Licensee”), a Delaware corporation having a principal place of business at 1616 Eastlake Ave. East, Suite 360, Seattle WA 98102.
LICENSE AGREEMENTLicense Agreement • January 13th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This License Agreement (this “Agreement”), effective on February 17, 2016 (the “Effective Date”) is by and between Flagship Pioneering Innovations V, Inc., a Delaware corporation (“Flagship”) and Cobalt Biomedicine, Inc. (formerly VL39, Inc.), a Delaware corporation] (“Company”). Flagship and Company may be referred to individually as a “Party” and collectively as the “Parties”.
AMENDED AND RESTATED EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • January 13th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
This amended and restated agreement (hereinafter “Agreement”), dated as of the Effective Date (defined below), is by and among the University of Rochester, an educational institution chartered by the State of New York and having its principal place of business at 601 Elmwood Avenue, Box URV, Rochester, New York 14642 (“University”), Oscine Corp., a Delaware corporation (“Oscine Corp”) and Sana Biotechnology, Inc., a Delaware corporation (“Sana”).
AMENDMENT TO LICENSE AGREEMENTLicense Agreement • January 13th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Amendment to the License Agreement (this “Amendment”) is effective as of June 10, 2019 (the “Amendment Effective Date”) and is entered into by and between Sana Biotechnology, Inc., a corporation existing under the laws of Delaware, having a place of business at 1616 Eastlake Avenue East, Suite 360, Seattle, WA 98102 (“Sana”), and President and Fellows of Harvard College, an educational and charitable corporation existing under the laws and the constitution of the Commonwealth of Massachusetts, having a place of business at Richard A. and Susan F. Smith Campus Center, Suite 727, 1350 Massachusetts Avenue, Cambridge, MA 02138 (“Harvard”).
CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED AMENDMENT NO. 1 TO NON-EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • March 16th, 2023 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Amendment to Non-Exclusive License And Development Agreement (“Amendment No. 1”), effective as of April 12, 2021 (“Amendment No. 1 Effective Date”), is entered into by and between FUJIFILM CELLULAR DYNAMICS, INC., having a place of business at 525 Science Drive, Madison, WI 53711 (“FCDI”), and SANA BIOTECHNOLOGY, INC., having a place of business at 188 East Blaine Street, Suite 400, Seattle, WA 98102 (“Licensee”).
AMENDMENT TO AGREEMENT AND PLAN OF MERGERAgreement and Plan of Merger • January 13th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Amendment, dated as of January 29, 2019 (the “Amendment”), to the Agreement and Plan of Merger, dated as of December 20, 2018 (this “Agreement”), is entered into by and among Sana Biotechnology, Inc., a Delaware corporation (“Parent”), Sana Biotechnology, IV, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), Cobalt Biomedicine, Inc., a Delaware corporation (the “Company”), and VentureLabs VI, Inc., a Delaware corporation, solely in its capacity as the Stockholders’ Representative (“Stockholders’ Representative”).
STOCK PURCHASE AGREEMENT by and among SANA BIOTECHNOLOGY, INC., OSCINE HOLDINGS, LLC, and each of the members of OSCINE HOLDINGS, LLC, dated as of September 10, 2020Stock Purchase Agreement • January 13th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
This STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of September 10, 2020, is by and among Sana Biotechnology, Inc., a Delaware corporation (“Purchaser”), Oscine Holdings, LLC, a Delaware limited liability company (“Seller”), and each of the Seller Members (as defined herein) and, together with Seller, the “Sellers”).
CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED Third Amendment to License AgreementLicense Agreement • March 16th, 2022 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Third Amendment (this “Third Amendment”), is effective as of May 20, 2021 (the “Third Amendment Effective Date”), by and between The President an Fellows of Harvard University (“Harvard”), and Sana Biotechnology, Inc., a corporation organized and existing under the laws of the State of Delaware (“Licensee”) (together with Harvard, the “Parties” and each individually a “Party”), and amends that certain License Agreement, dated as of March 19, 2019, as amended by those certain Amendments to the License Agreement dated as of June 10, 2019, and December 15, 2020, by and between Harvard and Licensee (together, the “Agreement”). Capitalized terms used but not defined herein have the respective meanings assigned to them in the Agreement.
THIRD AMENDMENT TO AGREEMENT AND PLAN OF MERGERAgreement and Plan of Merger • May 5th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Third Amendment (“Third Amendment”), dated as of March 22, 2021 (the “Third Amendment Effective Date”), to Agreement and Plan of Merger is entered into by and between Sana Biotechnology, Inc., a Delaware corporation (“Parent”), and VentureLabs VI, Inc., a Delaware corporation, solely in its capacity as the Stockholders’ Representative (“Stockholders’ Representative”), and amends that certain Agreement and Plan of Merger dated as of December 20, 2018 by and among Parent, Stockholders’ Representative, Sana Biotechnology, IV, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Cobalt Biomedicine, Inc., a Delaware corporation (the “Company”), as amended by those certain amendments thereto dated as of January 29, 2019, and February 8, 2019 (the “Agreement”).
CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED AMENDMENT NO. 3 TO OPTION AND LICENSE AGREEMENTOption and License Agreement • May 8th, 2023 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 3 to Option and License Agreement (the “Third Amendment”) is made as of March 17, 2023 (the “Third Amendment Effective Date”), by and between Beam Therapeutics Inc., a Delaware corporation having an office at 238 Main Street, Cambridge, MA 02142 (“Beam”), and Sana Biotechnology, Inc., a Delaware corporation having an office at 188 E Blaine Street, #400, Seattle, WA 98102 (“Sana”). Sana and Beam are referred to in this Third Amendment individually as a “Party” and collectively as the “Parties”.
FOURTH AMENDMENT TO LICENSE AGREEMENTLicense Agreement • March 16th, 2022 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Fourth Amendment (this “Fourth Amendment”), is effective as of October 25, 2021 (the “Fourth Amendment Effective Date”), by and between President an Fellows of Harvard University (“Harvard”), and Sana Biotechnology, Inc., a corporation organized and existing under the laws of the State of Delaware (“Licensee”) (together with Harvard, the “Parties” and each individually a “Party”), and amends that certain License Agreement, dated as of March 19, 2019, as amended by those certain Amendments to the License Agreement dated as of June 10, 2019, December 15, 2020, and May 20, 2021, by and between Harvard and Licensee (together, the “Agreement”). Capitalized terms used but not defined herein have the respective meanings assigned to them in the Agreement.
Amendment NO. 5 to EXCLUSIVE START-UP LICENSE Agreement between SANA BIOTECHNOLOGY, INC. and UNIVERSITY OF WASHINGTONOriginal Agreement • November 2nd, 2022 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 5 (“Amendment No. 5”), with an effective date of as of the date of the last signature (“Amendment No. 5 Effective Date”), is entered into by and between Sana Biotechnology, Inc. (“Company”) and University of Washington (“University”).
Amendment NO. 6 to EXCLUSIVE START-UP LICENSE Agreement between SANA BIOTECHNOLOGY, INC. and UNIVERSITY OF WASHINGTONOriginal Agreement • November 2nd, 2022 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 6 (“Amendment No. 6”), with an effective date as of the date of the last signature (“Amendment No. 6 Effective Date”), is entered into by and between Sana Biotechnology, Inc. (“Company”) and University of Washington (“University”).
AMENDMENT NO. 1 TO PATENTS SUB-LICENSE AGREEMENTSub-License Agreement • January 13th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 to Patents Sub-License Agreement (“Amendment No. 1”), effective as of 26 May 2020 (“Amendment No. 1 Effective Date”), is entered into by and between LA SOCIETE PULSALYS, a company organized under French Law, having its registered office at [***] (“Pulsalys”), Cobalt Biomedicine, Inc. a Delaware corporation having offices at [***] (“Cobalt”), and Sana Biotechnology, Inc. a Delaware corporation having offices at 188 East Blaine St., Seattle WA, 98102 (“Sana”).
LEASE AGREEMENT BETWEEN PACIFIC COMMONS OWNER, LP, a Delaware limited partnership, AS LANDLORD ANDLease Agreement • August 4th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances) • California
This Lease Agreement ("Lease") is made and entered into as of July 13, 2021, by and between PACIFIC COMMONS OWNER, LP, a Delaware limited partnership ("Landlord") and Sana Biotechnology, Inc., a Delaware corporation ("Tenant").
Amendment NO. NINE (9) to [***] EXCLUSIVE START-UP LICENSE Agreement between Sana biotechnology, Inc. and UNIVERSITY OF WASHINGTONOriginal Agreement • November 2nd, 2022 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 9 (“Amendment No. 9”), with an effective the date of last signature (“Amendment No. 9 Effective Date”), is entered into by and between Sana Biotechnology, Inc. (“Company”) and University of Washington (“University”).
FIRST AMENDMENT TO LICENSE AGREEMENTLicense Agreement • January 13th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This FIRST AMENDMENT TO LICENSE AGREEMENT (this “First Amendment”), entered into as of February 14, 2019 (the “First Amendment Date”), is made and entered into by and between Flagship Pioneering Innovations V, Inc., a Delaware corporation (“Flagship”) and Cobalt Biomedicine, Inc. (formerly VL39, Inc.), a Delaware corporation (“Company”).
PATENT LICENSE AGREEMENT – EXCLUSIVEPatent License Agreement – Exclusive • March 16th, 2022 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances) • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options).
Amendment NO. SEVEN (7) to EXCLUSIVE START-UP LICENSE Agreement between SANA BIOTECHNOLOGY, INC. and UNIVERSITY OF WASHINGTONOriginal Agreement • November 2nd, 2022 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 7 (“Amendment No. 7”), with an effective date of as of the date of the last signature (“Amendment No. 7 Effective Date”), is entered into by and between Sana Biotechnology, Inc. (“Company”) and University of Washington (“University”).
AMENDMENT NO. 4 TO EXCLUSIVE START-UP LICENSE AGREEMENT BETWEEN SANA BIOTECHNOLOGY, INC. AND UNIVERSITY OF WASHINGTONOriginal Agreement • January 28th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 4 (“Amendment No. 4”), with an effective date of January 21, 2021 (“Amendment No. 4 Effective Date”), is entered into by and between Sana Biotechnology, Inc. (“Company”) and University of Washington (“University”).
AMENDMENT NO. 1 TO EXCLUSIVE START-UP LICENSE AGREEMENT BETWEEN CYTOCARDIA, INC. AND UNIVERSITY OF WASHINGTONSana Biotechnology, Inc. • January 13th, 2021 • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 1 (“Amendment No. 1”), with an effective date of November 6, 2019 (“Amendment No. 1 Effective Date”), is entered into by and between Cytocardia, Inc. (“Company”) and University of Washington (“University”).
EXCLUSIVE LICENSE AGREEMENT between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and SANA BIOTECHNOLOGY, INC. forExclusive License Agreement • January 13th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances) • California
This exclusive license agreement (“Agreement”) is made effective this 2nd day of January, 2019 (“Effective Date”), by and between The Regents of the University of California, a California public corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 (“The Regents”) and acting through its Office of Technology Management, University of California San Francisco (“UCSF”), 600 16th Street, Suite S-272, San Francisco, CA 94143 and Sana Biotechnology, Inc., a Delaware corporation, having a place of business at 1616 Eastlake Avenue East, Suite 360, Seattle, WA 98102 (“Licensee”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE...The Exclusive License Agreement • February 29th, 2024 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
This First Amendment (the “First Amendment”) is made effective May 21, 2021 (the “First Amendment’s Effective Date”), by and between The Regents of the University of California, a California public corporation, having its statewide administrative offices at [***] (“The Regents”), acting through The Technology Development Group of the University of California, Los Angeles (“UCLA”), located at [***], and Sana Biotechnology, Inc. (“Licensee”), a Delaware Corporation having its principal place of business at 188 E. Blaine St., Suite 400, Seattle WA 98102, and amends the license agreement with Licensee, dated March 01, 2019 with UC Agreement Control Number [***] (the “Agreement”).
CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED OPTION AND LICENSE AGREEMENTOption and License Agreement • November 8th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
ASSIGNMENT AND AMENDMENT NO. 2 OF SEED BANK SUPPLY AGREEMENTSeed Bank Supply Agreement • January 13th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Assignment and Amendment No. 2 of Seed Bank Supply Agreement (“Assignment”), effective as of January 6, 2021 (“Assignment Effective Date”), is entered into by and among Hadasit Medical Research Services and Development Ltd., a company duly incorporated under the laws of Israel (“Hadasit”), Oscine Corp., a Delaware corporation (“Oscine”), and Sana Biotechnology, Inc., a Delaware corporation (“Sana”).
CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED AMENDMENT NO. 3 TO PATENTS SUB-LICENSE AGREEMENTPatents Sub-License Agreement • November 8th, 2023 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 3 to Patents Sub-License Agreement (“Amendment No. 3”), effective as of 31 July 2023 (“Amendment No. 3 Effective Date”), is entered into by and between LA SOCIETE PULSALYS, a company organized under French Law, having its registered office at [***] (French company registration number) [***], Code [***] (French principal activity code) [***] (“Pulsalys”) and Sana Biotechnology, Inc. a Delaware corporation having offices at 188 East Blaine St., Seattle WA, 98102 (“Sana”).
Certain confidential information contained in this document, marked by [***], has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) the type of information that the registrant treats as private...Patent License Agreement • February 29th, 2024 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 1 (“Amendment No. 1”), with an effective date of December 30, 2022 (“Amendment No. 1 Effective Date”), is entered into by and between Sana Biotechnology, Inc. (“Company”) and University of Rochester (“University”).
ASSIGNMENT OF LICENSE AGREEMENTAssignment of License Agreement • January 13th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Assignment of License Agreement (“Assignment”), effective as of November 11, 2020 (“Effective Date”), is entered into by and among the University of Washington, a public institution of higher education and an agency of the state of Washington, acting through UW CoMotion (“University”), Cytocardia, Inc. a Delaware corporation having offices at 188 East Blaine St., Seattle WA, 98102 (“Cytocardia”), and Sana Biotechnology, Inc. a Delaware corporation having offices at 188 East Blaine St., Seattle WA, 98102 (“Sana”).
LICENSE AGREEMENT by and between SANA BIOTECHNOLOGY, INC. And PRESIDENT AND FELLOWS OF HARVARD COLLEGE Dated as of March 19, 2019License Agreement • January 13th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This License Agreement (this “Agreement”) is entered into as of this 19th day of March, 2019 (the “Effective Date”), by and between Sana Biotechnology, Inc., a corporation existing under the laws of Delaware, having a place of business at 1616 Eastlake Avenue East, Suite 360, Seattle, WA 98102 (“Licensee”), and President and Fellows of Harvard College, an educational and charitable corporation existing under the laws and the constitution of the Commonwealth of Massachusetts, having a place of business at Richard A. and Susan F. Smith Campus Center, Suite 727, 1350 Massachusetts Avenue, Cambridge, Massachusetts 02138 (“Harvard”).
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT SANA BIOTECHNOLOGY, INC. FEBRUARY 13, 2019Investors’ Rights Agreement • January 13th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of February 13, 2019, by and among Sana Biotechnology, Inc. a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
